# JY016 Injection in Patients With Advanced Solid Tumors Expressing EGFR

> **NCT07510841** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Biotech Pharmaceutical Co., Ltd.** · enrollment: 228 (estimated)

## Conditions studied

- Solid Cancers

## Interventions

- **DRUG:** JY016

## Key facts

- **NCT ID:** NCT07510841
- **Lead sponsor:** Biotech Pharmaceutical Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-30
- **Primary completion:** 2029-05-31
- **Final completion:** 2029-05-31
- **Target enrollment:** 228 (ESTIMATED)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07510841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07510841, "JY016 Injection in Patients With Advanced Solid Tumors Expressing EGFR". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07510841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*